In Part 1 of 2 videos about squamous lung cancer, Dr. Chad Pecot explains what doctors look for and ask about when diagnosing lung cancer, and how you can be sure you received the correct diagnosis.

[powerpress]

The lung surgeons I work with are competitive, and the patients they treat are better for it. They monitor how many lymph nodes they are able collect from the mediastinoscopies and lung cancer surgeries they do, competing against their own targets and each other. Why?

This is the last part of my discussion with Dr. Matthew Horton, a pathologist with a special training and a great expertise in lung pathology who works here in Seattle at a company called CellNetix.

We focus in this last one on the increasing focus on molecular markers in making clinical decisions and how this is changing the relationship of pathologists with oncologists, as well as the need for pathologists to provide this information in a timely way.

Have you ever wondered how exactly your oncologist knew what kind of cancer you had when he/she told you or a loved one about your diagnosis, whether it was non-small cell lung cancer (such as squamous cell or adenocarcinoma), breast cancer, or colon cancer?

In my last post I outlined the typical clinical scenario for pneumonic bronchioloalveolar carcinoma (BAC), which is typically the mucinous subtype of this unusual disease. In fact, we are still actively learning a great deal about BAC, enough for the lung cancer experts to begin to develop a more sophisticated view that the mucinous and non-mucinous subtypes have different behaviors and respond differently to treatments.